Zhejiang Huahai Pharmaceutical has poached a senior quality executive from rival Jiangsu Hengrui Pharmaceuticals amid regulatory pressure on both Chinese drugmakers from the US Food and Drug Administration.
The move signals an aggressive push by Huahai to strengthen its quality leadership at a time when FDA manufacturing citations have intensified across the Chinese pharmaceutical sector.
Hengrui had accumulated a significant list of manufacturing failings identified by FDA inspectors, including poor contamination controls that raised serious concerns about product safety and consistency.
Inspectors also found that Hengrui had subpar cleaning protocols in place, which can lead to cross-contamination risks and threaten the integrity of drug production lines.
The FDA further cited Hengrui for failing to promptly hand over documentation to inspectors during the review process, a serious procedural violation that compounds the underlying manufacturing concerns.
Quality control shortfalls were also identified at Hengrui, rounding out what regulators described as a broad pattern of manufacturing missteps at the facility.
Huahai itself is no stranger to FDA scrutiny, having received a warning letter in June 2025 following an inspection of its Xunqiao facility in Linhai, Zhejiang Province, conducted in January 2025.
The warning letter outlined significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals, putting Huahai under considerable pressure to demonstrate improvement to regulators.
By recruiting a seasoned quality executive from Hengrui, Huahai appears to be betting that fresh leadership can help it navigate the regulatory challenges and restore confidence with the FDA.
Both companies are major players in the global generics and active pharmaceutical ingredient supply chain, meaning their manufacturing compliance has implications well beyond China’s domestic market.
The FDA has been increasing its scrutiny of overseas manufacturing facilities in recent years, and Chinese pharmaceutical plants have faced a particularly high level of inspection activity and enforcement action.
For Huahai, resolving its manufacturing compliance issues is critical to maintaining access to the US market, which remains one of the most lucrative destinations for Chinese pharmaceutical exporters.